Evaluation of vaccine response to 13-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine in patients living with HIV/AIDS

Phase 4

Recruiting

• Conditions: HIV Long-Term Survivors; Vaccine Immunogenicity; C01.221.250.875

• Registration Number: RBR-3wshg2m
• Lead Sponsor: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-06-29
• Last Update Posted: 26 July 2023
• Study Completion: 2026-12-30

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

HIV-infected patients confirmed by confirmatory tests (Western-Blott and/or HIV polymerase chain reaction viral load) who are of any gender identity. Being in regular use of highly effective antiretroviral, according to the definitions of the Ministry of Health, for at least four weeks. Minimum age 18 years old. Signature of the Free and Informed Consent Form (Appendix A) . For the control group: negative quick test for HIV

Exclusion Criteria

Patient with a history of anaphylactic reaction to pneumococcal conjugate vaccines (PCV-7, PCV-10 or PCV-13) or 23-valent pneumococcal polysaccharide vacines. Previous vaccination with PCV-7, PCV-10, PCV-13 (interference in the evaluation of the pre-vaccination humoral immune response). Have been vaccinated with PPV-23 less than 1 year ago. Transfusion of blood components or Immunoglobulins in the last 28 days before vaccination with PCV-13 or PPV-23. Blood dyscrasias that prevent intramuscular vaccine application; Fever in the last 24 hours before vaccination

Study & Design

• Study Type: Intervention
• Study Design: Not specified